

Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

Submission date 21/02/2006	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
Registration date 29/03/2006	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
Last Edited 10/07/2017	Condition category Circulatory System	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Narasimharajapura Rajendra

Contact details

Department of Clinical Pharmacology
Level 7
Ninewells Hospital
Dundee
United Kingdom
DD1 9SY

Additional identifiers

Protocol serial number

RAJ001

Study information

Scientific Title

Does allopurinol prevent adverse left ventricular remodelling post-myocardial infarction?

Study objectives

Allopurinol, by inhibiting xanthine oxidase brings about a reduction in reactive oxygen species, thereby preventing adverse remodelling

Ethics approval required

Old ethics approval format

Ethics approval(s)

Regional Ethics Committee, 07/12/2005, ref: 05/S1401/171

Study design

Randomised double-blind placebo-controlled parallel group

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Myocardial infarction

Interventions

Allopurinol versus placebo

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Allopurinol

Primary outcome(s)

Assessment of remodelling

Key secondary outcome(s)

Brain natriuretic peptide (BNP)

Completion date

02/04/2008

Eligibility**Key inclusion criteria**

Post myocardial infarction - days 3 to 14

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Renal failure
2. Concomitant warfarin therapy
3. Allopurinol allergy

Date of first enrolment

10/02/2006

Date of final enrolment

02/04/2008

Locations**Countries of recruitment**

United Kingdom

Scotland

Study participating centre

Ninewells Hospital

Dundee

United Kingdom

DD1 9SY

Sponsor information**Organisation**

University of Dundee (UK)

ROR

<https://ror.org/03h2bxq36>

Funder(s)

Funder type

Charity

Funder Name

British Heart Foundation

Alternative Name(s)

The British Heart Foundation, the_bhf, BHF

Funding Body Type

Private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration